Replies to post #32955 on Endonovo Therapeutics Inc (ENDV)

[Cornerstone_Marketing]

The company has the amazing results and is now moving forward with the plan to commercialize the asset. Clearly outlined and being followed.
Current valuation by leading firm for spinoff of medical asset expected to be 50-100 million - in progress
Spin-off expected to satisfy ALL existing debts and noteholders as well as give 80% of new company sofpulse inc to exisiting ENDV shareholders - on track
New telehealth division launched - on track
New PeMF division launched- on track
Securing of VA partner for federal procurment system- done
Adding international distributers some many more coming along with EU and Asia approvals-
Adding sponsorships and nationwide marketing companies for the DTC launch - done and continuing.
Seem like Ira and Alan are killing it and just getting started the “calm” before the revenue storm as they like to say. I bet the next few Q’s get VERY interesting as this goes worldwide and the plan continues!

[Biotech_Tradez]

They are not good results. Shows you the intent of the posts.

The study looked at the combination of PEMF and bupivicaine on post operative pain in mastectomy and reconstruction patients. Look at the pain scores they are no better than a placebo.

When your intent is to market stock, i.e. stock promotion, you will put lipstick on a pig and tell us it is the next Medtronic.

[Crash and berns]

Thanks for your post
I have a 50000 note with Alan and Endonovo
It is in default as of today and it has been extended 3 times
Because I need and want the note paid the company claims I should say noting and not go public
Sounds like to me there are a lot of people in same boat
All sinking
Time for class action suit and sec involvement
Not going to take this